To access the Live Streaming Sessons, CME Surveys and other symposium materials please login using your registration email address.
CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible from this website after logging in with the email address you submitted during registration. Surveys will be available online starting the first day of the symposium. You must complete the process by February 10, 2025 in order to receive your certificate. Certificates will be available online until August 1, 2025 and are printable directly from the website.
The AAFP has reviewed 25th Annual San Diego Heart Failure Winter Symposium - New Strategies for Detection, Prevention and Treatment of Heart Failure and deemed it acceptable for up to 11.5 Live AAFP Prescribed credits. Term of Approval is from 01/17/25 to 01/18/25. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as
equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's
Recognition Award. When applying for the AMA PRA, Prescribed credit earned
must be reported as Prescribed, not as Category 1.
The 25th Annual San Diego Heart Failure Winter Symposium - New Strategies for Detection, Prevention and
Treatment of Heart Failure. This year’s meeting will provide a comprehensive overview of strategies for detecting, preventing and treating heart failure. The talks, panel discussions and case presentations will focus on best practices and recent guideline recommendations as interpreted through the eyes of a renowned faculty. Throughout the two days, the faculty will provide expert insight and personal experience as they discuss the full range of management options that are available for patients throughout the spectrum of heart failure, ranging from Stage A (asymptomatic patients with risk factors) all the way to Stage D heart failure (highly symptomatic end-stage patients). New approaches for diagnosing heart failure and identifying specific groups of patients that require special management considerations (such as amyloid, hypertrophic and genetic cardiomyopathies) will be highlighted, rationale for guideline directed medical therapies (GDMTs) will be reviewed and strategies for successful implementation will be presented.
The Symposium combines didactic talks, panel discussions, case presentations and patient perspectives to provide a full and balanced overview of relevant management issues. The four highly focused sessions that comprise this year’s Symposium will cover topics related to Populations and Patients at Risk (Session I), Amyloid Heart Disease, Infiltrative Heart Disease, Hypertrophic and Other Forms of Inherited Cardiomyopathy (Session II), Identifying and Treating Heart Failure (Session III), Cardiogenic Shock, Percutaneous Devices to Support Cardiac Function, Emerging Strategies for Preventing Sudden Cardiac Death and Advances in Catheter Based Treatment of Atrial Fibrillation and Valvular Disease (Session IV). During each session, the audience will have an opportunity to comment on the talks and question the faculty on their thoughts about the best approaches for patient management. Our goal, as always, is to provide cutting edge information in a format that will enhance adaption of the knowledge that is gained into clinical practice.
This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.
At the conclusion of this activity, participants should be able to:
Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year. Heart failure is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. Data shows us that while heart failure is common, it is oftentimes unrecognized and misdiagnosed. Recent data also indicate that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585). There is also significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF that has led to a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S., patients with HF received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010). As a consequence, despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.
This activity is in compliance with California Assembly Bills 1195 and 241 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity.
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.